Evaluation of Effectiveness and Safety of PROMUS Element Stent (IRIS-ELEMENT )
Launched by SEUNG-JUNG PARK · May 9, 2011
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
The Element Stent platform features a proprietary Platinum Chromium Alloy, designed specifically for coronary stents. This alloy, coupled with a new stent architecture, is designed to enable thinner struts, increased flexibility and a lower profile while improving radial strength, recoil and visibility. In addition, the PROMUS Element Stent System incorporates the new Apex™ Dilatation Catheter technology, designed to enhance deliverability to complex lesions.
Currently, there have been limited data regarding comparison of PROMUS Element stent with first-generation DES in routine clinical p...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients receiving Promus Element stents
- • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
- Exclusion Criteria:
- • Patients with a mixture of other DESs
- • Terminal illness with life expectancy \<1 year
- • Patients with cardiogenic shock
About Seung Jung Park
Seung-Jung Park is a distinguished clinical trial sponsor recognized for his commitment to advancing medical research and innovation. With a focus on cardiology and interventional procedures, he leads initiatives that aim to improve patient outcomes through rigorous clinical trials. His expertise in trial design and execution ensures adherence to the highest ethical standards and regulatory requirements. By fostering collaboration among multidisciplinary teams, Seung-Jung Park drives the development of cutting-edge therapies, contributing significantly to the scientific community and enhancing the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Seung-Jung Park, MD, PhD
Principal Investigator
Asan Medical Center
Ki Bae Seung, MD, PhD
Principal Investigator
Seoul St. Mary's Hospital, Catholic University of Korea
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials